References
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727–733.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020 Mar 26;382(13):1199–1207.
- Watson OJ, Barnsley G, Toor J, et al. Global impact of the first year of COVID-19 vaccination: a mathematical modelling study. Lancet Infect Dis. 2022 Sep;22(9):1293–1302.
- WHO. Coronavirus disease (COVID-19): Vaccines 2022 [cited 2022 Nov 21]. Available from: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-covid-19-vaccines
- WHO. Interim recommendations for use of the Cansino Ad5-nCoV-S vaccine (Convidecia ®) against COVID-19 19 May 2022; [cited 2022 Nov 24]. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE-recommendation-Ad5-nCoV-Convidecia
- Halperin SA, Ye L, MacKinnon-Cameron D, et al. Final efficacy analysis, interim safety analysis, and immunogenicity of a single dose of recombinant novel coronavirus vaccine (adenovirus type 5 vector) in adults 18 years and older: an international, multicentre, randomised, double-blinded, placebo-controlled phase 3 trial. Lancet. 2022 Jan 15;399(10321):237–248.
- Organization WH Strategy to achieve global Covid-19 vaccination by mid-2022 2021 [cited 2021 Jun 23]. Available from: https://www.who.int/publications/m/item/strategy-to-achieve-global-covid-19-vaccination-by-mid-2022
- Organization WH. Global COVID-19 vaccination strategy in a changing world: July 2022 update. 2022 [cited 2022 Nov 24]. Available from: https://www.who.int/publications/m/item/global-covid-19-vaccination-strategy-in-a-changing-world–july-2022-update
- So AD, Woo J. Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis. BMJ. 2020 Dec 15;371:m4750. doi: 10.1136/bmj.m4750.
- AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19 [Internet]. 2020. Available from: https://www.astrazeneca.com/media-centre/press-releases/2020/azd1222hlr.html#!
- Johnson & Johnson initiates pivotal global phase 3 clinical trial of Janssen’s COVID-19 vaccine candidate [Internet]. 2020. Available from: https://www.jnj.com/johnson-johnson-initiates-pivotal-global-phase-3-clinical-trial-of-janssens-covid-19-vaccine-candidate
- Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020 Aug 15;396(10249):479–488.
- Organization WH. Guidelines on clinical evaluation of vaccines regulatory expectations 2004 [cited 2022 Jul 11]. Available from https://www.who.int/publications/m/item/guidelines-on-clinical-evaluation-of-vaccines-regulatory-expectations
- Center for Drug Evaluation N. Guidance of clinical comparability research guidelines for preventive vaccines 2019 [cited 2023 Jul 4]. Available from: https://www.cde.org.cn/main/fullsearch/fullsearchpage
- Chen C, Lu FC. The guidelines for prevention and control of overweight and obesity in Chinese adults. Biomed Environ Sci. 2004;17(Suppl):1–36.
- Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020 Jun 13;395(10240):1845–1854.
- Nauta J. Statistics in clinical vaccine trials. Springer Berlin Heidelberg: 2010. doi:10.1007/978-3-642-14691-6
- FDA. Emergency use authorization for vaccines to prevent COVID-19; guidance for industry Mar 31, 2022 [cited 2022 Nov 17]. Available from: https://www.fda.gov/media/142749
- Salazar E, Kuchipudi SV, Christensen PA, et al. Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization. J Clin Invest. 2020 Dec 1;130(12):6728–6738.
- Logunov DY, Dolzhikova IV, Zubkova OV, et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020 Sep 26;396(10255):887–897.
- Li J, Hou L, Guo X, et al. Heterologous AD5-Ncov plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial. Nat Med. 2022 Feb;28(2):401–409.
- Planas D, Saunders N, Maes P, et al. Considerable escape of SARS-CoV-2 Omicron to antibody neutralization. Nature. 2022 Feb;602(7898):671–675.
- Liu L, Iketani S, Guo Y, et al. Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. Nature. 2022 Feb;602(7898):676–681.